
Jubilant Ingrevia Q1 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 1
Fundraise
N/A
Order
Yes
Capex
Yes
3 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- Jubilant Ingrevia aims to grow revenue 3x from FY24 to FY29, targeting Rs. 12,000 to Rs. 13,000 crore+ revenue.
- Specialty Chemicals business expected to grow steadily with 23%-25% EBITDA margin aspirational target.
- CDMO business (Pharma and Agro) to grow at least 20%-25% annually, with several advanced-stage opportunities to convert.
- Agrochemical demand and volumes expected to recover gradually with easing inventory destocking; growth moderated but steady.
- Nutrition business volumes increased ~14%-15% QoQ, with future improvement hinging on new food/cosmetic grade products launching in Q3 FY25.
- New product lines (diketene, food-grade choline bitartrate) showing strong traction and contributing to volume growth.
- Overall specialty segments reported stable or increasing volumes seasonally, with expectations of volume growth in FY25 compared to FY24.
- Continued focus on customer centricity and ramping up new plants to sustain growth momentum.
See what Jubilant Ingrevia management said on margin guidance — free account, 30 seconds.
Fundraise plans
- No explicit mention of any current or upcoming fundraising through debt or equity in the transcript.
- Capital expenditure during the quarter was Rs.116 crore, primarily funded through internal accruals.
- The company’s net debt as of June 30, 2024, was Rs.677 crore with a net debt-to-equity ratio of 1.5x based on trailing 12-month EBITDA.
- No indication from management about plans for incremental debt or equity raising.
- Focus appears to be on internal funding for expansion and ongoing initiatives.
See what Jubilant Ingrevia management said on order book — free account, 30 seconds.
Capex plans
Yes- Commissioned an agrochemical plant in January 2024 capable of producing both intermediates and active ingredients; currently under evaluation.
- Plans to undertake modifications and incremental CAPEX in the agrochemical plant to meet demand.
- Significant investment has already been made in the new agrochemical plant.
- Expansion plans for fine chemicals with multipurpose plants at Gajraula and Bharuch facilities expected to serve growth for the next five years.
- Ongoing CAPEX of Rs. 116 crore in Q1 FY25 funded primarily through internal accruals.
- Multiple initiatives under "Pinnacle 345" growth roadmap, including investments in high potential product categories and sustainability efforts such as sourcing renewable energy.
- CDMO business expected to grow with steady investments, targeting 25%-30% year-on-year growth; includes pharma, agro, and semiconductor opportunities.
Track Jubilant Ingrevia — get its next earnings analysis in your feed
How does Jubilant Ingrevia rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Jubilant Ingrevia rank in Chemicals & Petrochemicals?
Compare Jubilant Ingrevia against every Chemicals & Petrochemicals company (Q1 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Jubilant Ingrevia's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…